Zevra Therapeutics, Inc.
NASDAQ:ZVRABiotechnology
+$0.31 today
- Market cap
- $559.34M
- Beta
- 0.89
- P/E (TTM)
- 6.1
- EPS (TTM)
- $2.13
Volume 0.84M
Average 1.43M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Zevra Therapeutics, Inc.
NASDAQ:ZVRA
Intrinsic Alpha fair value
Locked
Current Price
$9.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +10.0% (5yr)4 analysts |
| Revenue | N/A | N/A | +118.8% | +22.4% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | +8.4% (5yr)5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +118.8% over three years. Forward estimates point to Revenue at +22.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Neurocrine Biosciences, Inc. NASDAQ:NBIX | $16.94B | $167.40 | Undervalued | 23.8 | +19.69% |
Jazz Pharmaceuticals plc NASDAQ:JAZZ | $15.50B | $241.55 | Undervalued | 476.3 | +33.34% |
Praxis Precision Medicines, Inc. NASDAQ:PRAX | $9.17B | $328.13 | Not rated | -25.0 | +65.68% |
Alkermes plc NASDAQ:ALKS | $7.90B | $47.03 | Undervalued | 49.1 | +55.33% |
Xenon Pharmaceuticals Inc. NASDAQ:XENE | $3.98B | $40.48 | Not rated | -12.1 | -4.51% |
Supernus Pharmaceuticals, Inc. NASDAQ:SUPN | $1.73B | $29.72 | Overvalued | -87.6 | -35.32% |
GH Research PLC NASDAQ:GHRS | $1.31B | $19.10 | Not rated | -23.8 | +32.87% |
Alto Neuroscience, Inc. NYSE:ANRO | $1.18B | $29.54 | Not rated | -9.8 | +68.88% |
MapLight Therapeutics, Inc. NASDAQ:MPLT | $308.98M | $7.25 | Not rated | -2.8 | -55.82% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $80.59M | $0.43 | Not rated | -1.2 | -87.42% |
Continue the stock analysis
Jump to another research area for this company.